[go: up one dir, main page]

AU2023367107A1 - N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof - Google Patents

N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof Download PDF

Info

Publication number
AU2023367107A1
AU2023367107A1 AU2023367107A AU2023367107A AU2023367107A1 AU 2023367107 A1 AU2023367107 A1 AU 2023367107A1 AU 2023367107 A AU2023367107 A AU 2023367107A AU 2023367107 A AU2023367107 A AU 2023367107A AU 2023367107 A1 AU2023367107 A1 AU 2023367107A1
Authority
AU
Australia
Prior art keywords
composition
dmt
film
acid
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023367107A
Other languages
English (en)
Inventor
Majed Fawaz
Prerak Patel
Santnu PATEL
Srinivas G Rao
Glenn Short
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atai Therapeutics Inc
Original Assignee
Atai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/974,443 external-priority patent/US20230136824A1/en
Application filed by Atai Therapeutics Inc filed Critical Atai Therapeutics Inc
Publication of AU2023367107A1 publication Critical patent/AU2023367107A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023367107A 2022-10-26 2023-10-26 N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof Pending AU2023367107A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/974,443 US20230136824A1 (en) 2021-04-26 2022-10-26 N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
US17/974,443 2022-10-26
PCT/US2023/077879 WO2024092106A2 (fr) 2022-10-26 2023-10-26 Compositions d'analogues de n-n-diméthyltryptamine (dmt) et de dmt, leurs procédés de fabrication et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
AU2023367107A1 true AU2023367107A1 (en) 2025-03-27

Family

ID=90832092

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023367107A Pending AU2023367107A1 (en) 2022-10-26 2023-10-26 N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof

Country Status (6)

Country Link
EP (1) EP4608395A2 (fr)
AR (1) AR130877A1 (fr)
AU (1) AU2023367107A1 (fr)
CA (1) CA3267555A1 (fr)
TW (1) TW202423415A (fr)
WO (1) WO2024092106A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
MX2023013928A (es) 2021-05-25 2023-12-08 Atai Therapeutics Inc Nuevas sales y formas cristalinas de sales de n,n-dimetiltriptamina.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021003467A1 (fr) * 2019-07-04 2021-01-07 Sw Holdings, Inc. Compositions de dosage et procédés d'utilisation de composés psychédéliques
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
IL297861A (en) * 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
EP4595962A3 (fr) * 2020-06-12 2025-10-22 Beckley Psytech Limited Composition pharmaceutique
EP4214192A4 (fr) * 2020-09-20 2024-09-25 Tactogen Inc. Compositions de tryptamine avantageuses pour troubles mentaux ou amélioration mentale
BR112023022195A2 (pt) * 2021-04-26 2024-01-16 Atai Therapeutics Inc Novas composições e métodos de n,n-dimetiltriptamina

Also Published As

Publication number Publication date
AR130877A1 (es) 2025-01-29
CA3267555A1 (fr) 2024-05-02
WO2024092106A2 (fr) 2024-05-02
TW202423415A (zh) 2024-06-16
EP4608395A2 (fr) 2025-09-03
WO2024092106A3 (fr) 2024-06-06

Similar Documents

Publication Publication Date Title
US12128027B2 (en) N—N-dimethyltryptamine (DMT) and DMT analog compositions, methods of making, and methods of use thereof
RU2436565C2 (ru) Распадающиеся пероральные пленки
EA031156B1 (ru) Сублингвальные пленки
TWI343263B (en) Patches for mucosa of oral cavity containing fentanyl
EP4608395A2 (fr) Compositions d'analogues de n-n-diméthyltryptamine (dmt) et de dmt, leurs procédés de fabrication et leurs procédés d'utilisation
WO2020086673A1 (fr) Système d'administration transmucosale orale de kétamine
EP3505161A1 (fr) Composition pharmaceutique sublinguale d'édaravone et de (+)-2-bornéol
EP4076380B1 (fr) Système thérapeutique transmucosal contenant de l'agomélatine
JP2013515782A (ja) オンダンセトロンを含む経口投与可能なフィルム製剤
JP2020535162A (ja) 増強された送達のエピネフリン及びプロドラッグ組成物
US20210244656A1 (en) Isotretinoin oral-mucosal formulations and methods for using same
WO2019165993A1 (fr) Composition pharmaceutique, procédé de préparation et utilisation de cette dernière
EP4076381B1 (fr) Système thérapeutique transmucosal contenant de l'agomélatine
KR20250156085A (ko) 레미마졸람을 포함하는 구강 점막 전달 시스템
JP2019523212A (ja) 局所麻酔の投与のための速効性の口腔内崩壊フィルム
CN114452255A (zh) 一种阿戈美拉汀微乳、微乳凝胶及其制备方法
WO2025076151A1 (fr) N-n-diméthyltryptamine (dmt) et compositions de film transmucosal oral analogique à base de dmt, leurs procédés de production et leurs méthodes d'utilisation
JP2006070027A (ja) 口腔粘膜投与剤
TWI897768B (zh) 阿哌沙班膜產品用於治療血栓症之用途
HK40082930A (en) Transmucosal therapeutic system containing agomelatine
HK40082930B (en) Transmucosal therapeutic system containing agomelatine
CN120131532A (zh) 秋水仙碱透皮给药凝胶及其制备方法
HK40082929B (en) Transmucosal therapeutic system containing agomelatine
HK40082929A (en) Transmucosal therapeutic system containing agomelatine
OA20027A (en) Isotretinoin oral-mucosal formulations and methods for using same.